cdc-coteauxdegaronne
» » Drug Resistance in Leukemia
eBook Drug Resistance in Leukemia  ePub

eBook Drug Resistance in Leukemia ePub

by Gert-Jan L. Kaspers

  • ISBN: 3718653877
  • Category: Medicine
  • Subcategory: Medicine
  • Author: Gert-Jan L. Kaspers
  • Language: English
  • Publisher: CRC Press; 1 edition (January 1, 1993)
  • Pages: 436
  • ePub book: 1183 kb
  • Fb2 book: 1467 kb
  • Other: txt azw docx lrf
  • Rating: 4.3
  • Votes: 706

Description

Cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. 337. Treatment of children with poor prognosis relapsed acute lymphoblastic

The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. Treatment of children with poor prognosis relapsed acute lymphoblastic. 345. Drug resistance testing as a basis for tailored therapy in children with. 353. A feasibility study of the MTT assay for chemosensitivity testing. 359. Acute myeloid leukemia AML sensitivity to antiblastics. 365. 10 years and 2000 tests further on.

Drug Resistance in Leukemia & Hardcover – 1 January 1993. by Gert-Jan L. Kaspers (Author). Book by Gert-Jan L. Kaspers.

General mechanisms of resistance are discussed, including the drug resistance related proteins p­ glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and erases. The Lung Resistance Protein (LRP) Predicts Poor Outcome in Acute Myeloid Leukemia. Pirker, Robert (et a.

Drug Resistance in Le. .See a Problem? We’d love your help.

Are you Gert-Jan L Kaspers? Register this Author. Molecular Drug Imaging: Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. Register with ORCID iD. PUBLICATIONS 8. Gert-Jan L Kaspers. Are you Gert-Jan L Kaspers? Register this Author. Authors: Marc H Jansen Sophie E M Veldhuijzen van Zanten Dannis G van Vuurden Marc C Huisman Danielle J Vugts Otto S Hoekstra Guus A van Dongen Gert-Jan L Kaspers. J Nucl Med 2017 May 20;58(5):711-716.

cle{R, title {Cellular drug resistance in childhood leukemia}, author {A. J. P. Veerman and Gertjan J L Kaspers and Raymond Pieters}, journal {Annals of Hematology}, year {1994}, volume {69}, pages {S31-S34} }. A. Veerman, Gertjan J L Kaspers, Raymond Pieters. Published in Annals of Hematology 1994. Drug resistance testing as a basis for tallored therapy in children with refractory or relapsed acute lymphoblastic leukemia. R Hartmann, S Schober, +3 authors G Henze.

Drug Resistance in Leukemia and Lymphoma.

Описание: This volume covers all important aspects of drug resistance in leukemia and lymphoma

Описание: This volume covers all important aspects of drug resistance in leukemia and lymphoma. General mechanisms of resistance are discussed, including the drug resistance related proteins, MRP (multi drug resistance protein) and LRP (lung resistance protein), and the role of glutathione.

Moreover, the progression of chronic myelogenous leukemia (CML) to blast crisis in patients was correlated with down-modulation of C/EBPalpha.

Kaspers, R. Pieters, . Cite this publication. Anna Grigorievna Turkina. Moreover, the progression of chronic myelogenous leukemia (CML) to blast crisis in patients was correlated with down-modulation of C/EBPalpha. line, derived from BCR-ABL+ CML in blast crisis, expressed wild-type C/EBPepsilon protein but not a functional C/EBPalpha, -beta, and -gamma.

To evaluate the frequency and the prognostic value of different mechanisms of drug resistance in acute leukemias, we investigated the expression of mdr1 by immunocytochemistry, mRNA slot blot or RT-PCR in 182 cases of adult acute myeloid and 37 cases of adult lymphoblastic leukemia. Before treatment, 39% of de novo AML, 38% of secondary AML, and 7% of de novo ALL exhibited a high level of mdr1 mRNA. After chemotherapy, the frequency of mdr1 gene expression in ALL raised dramatically to 60% (P < . 05), while no significant change was found for AML cases.

The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols.